FDA Asks How Far Eagle’s Bendeka Exclusivity Should Extend

Drug Industry Daily
The FDA has invited applicants for certain products containing bendamustine to share how broad of a scope they believe Eagle Pharmaceuticals’ seven-year orphan drug exclusivity for Bendeka (bendamustine) should be, and if it should apply to Treanda.

To View This Article:


Subscribe To Drug Industry Daily